Characterization and molecular modeling of the inclusion complexes of 2-(2-nitrovinyl) furan (G-0) with cyclodextrines

The objective of this study was to prepare and characterize complexes of 2-(2-nitrovinyl) furan (G-0) with 2-hydroxypropyl-β-cyclodextrin (HP-β-CD) and sulfobutyl ether-β-cyclodextrin (SBE-β-CD). The solid inclusion complexes were prepared using kneading and freeze-drying methods. Phase solubility p...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of pharmaceutics 2012-12, Vol.439 (1-2), p.275-285
Hauptverfasser: Ruz, Vivian, Froeyen, Mathy, Busson, Roger, González, Mirtha M., Baudemprez, Luc, Van den Mooter, Guy
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The objective of this study was to prepare and characterize complexes of 2-(2-nitrovinyl) furan (G-0) with 2-hydroxypropyl-β-cyclodextrin (HP-β-CD) and sulfobutyl ether-β-cyclodextrin (SBE-β-CD). The solid inclusion complexes were prepared using kneading and freeze-drying methods. Phase solubility profiles were used to obtain the apparent stability constants and the complexation efficiency. They were classified as AL type for both systems: the apparent stability constants K1:1 of the complexes were 48.7 and 79.2M−1 for HP-β-CD and SBE-β-CD respectively. The solid inclusion complexes were evaluated by means of differential scanning calorimetry (DSC), X-ray diffraction (XRD) and nuclear magnetic resonance spectroscopy (NMR). Especially the use of the two-dimensional ROESY spectrum was useful to confirm the presence of an inclusion complex. The spatial configuration of the drug inside the cyclodextrin cavity was investigated using molecular modeling studies. The latter results were in agreement with the experimental data. Inclusion complexes of G-0 with HP-β-CD contributed to improve the chemical stability of the drug in the presence of other commonly used pharmaceutical excipients.
ISSN:0378-5173
1873-3476
DOI:10.1016/j.ijpharm.2012.09.025